期刊
BIOMARKERS IN MEDICINE
卷 10, 期 8, 页码 797-810出版社
FUTURE MEDICINE LTD
DOI: 10.2217/bmm-2016-0096
关键词
anti-oxidized phospholipid antibodies; anti-oxidized phospholipid defense; biomarker potential; cardiovascular disease; ELISA; oxidized phospholipids
资金
- Stiftung fur Herzkreislaufkrankheiten
- Swiss Heart Foundation
- Fonds zur Forderung wissenschaftlicher Forschung [P27682-B30, P22267-B11]
Aim: Oxidized phospholipids (OxPL) are the major pathogenic component of oxidized low-density lipoproteins (OxLDL). Endogenous anti-OxPL activity, defined as the ability to neutralize adverse effects of oxidized lipids, may have biomarker potential. Methods & results: Using two anti-OxPL monoclonal antibodies (commercial mAB-E06 and custom mAB-509) we developed a novel ELISA that measures the global capacity of plasma to inactivate OxPL. Preincubation of OxLDL with plasma inhibits its binding of anti-OxPL mABs. This phenomenon ('masking') reflects anti-OxPL plasma activity. A pilot clinical application of the assay revealed reduced anti-OxPL activity in hypertension, coronary artery disease, acute coronary syndrome and diabetes. Conclusion: Inadequate anti-OxPL protection may contribute to cardiovascular disease and have biomarker potential in conditions associated with abnormal lipid peroxidation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据